TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Business Development

Nestlé Health Science buys Seres Therapeutics commercial asset
Terms undisclosed
Fecal microbiota spores, clostridioides difficile infection - Read more

THE GOOD
Clinical Trials

Oopsie; Boehringer Ingelheim, Zealand Pharma have positive Ph2 data, but it was “unintentionally” published early
GLP-1, metabolic dysfunction-associated steatohepatitis (MASH) - Read more

Abbvie’s $10.1B ImmunoGen buy-out delivers Ph2 win
Antibody-drug conjugate, ovarian cancer - Read more

Replimune stock shoots to the mune on positive Ph1/2 data
Oncolytic herpes simplex virus, melanoma, cancer - Read more

Edwards Lifesciences releases 5-year aortic valve data
Medical device, aortic valve replacement, small aortic annulus - Read more

THE GOOD
Fundraises

Nucleus RadioPharma Series A Extension (amount undisclosed)
CDMO, radiopharmaceuticals - Read more

Isotope Technologies Munich (ITM) €188 ($205M) fundraise
Radiopharmaceuticals, gastrointestinal cancer - Read more

Structure Therapeutics $476M upsized public offering
GLP-1, weight-loss - Read more

Advanced Medicine Partners $32M financing
Cell & gene therapy, viral vectors, CDMO - Read more

THE GOOD
Investments

Orano Med debuts US manufacturing site
Radiopharmaceuticals, alpha therapies, cancer - Read more

THE GOOD
Mergers & Acquisitions

GSK buys Elsie Biotechnologies for $50M
Oligonucleotide, hepatitis B, steatotic liver disease - Read more

Vanda Pharmaceuticals courting $466M bid from Cycle Pharmaceuticals
Small molecule, schizophrenia, bipolar I disorder - Read more

THE GOOD
Partnerships

Sanofi’s going postal in France with DHL
Patient access, logistics - Read more

Charles River Laboratories, Sanofi partner on virtual control animals
Simulations, animal testing, machine learning - Read more

THE GOOD
Product Launches

Moon Surgical hears sweet music with FDA go-ahead for Maestro surgical robot
Surgery robot, medical device, laparoscopy - Read more

THE GOOD
Public Health

CDC now recommending doxycycline within 72h of unprotected sex to prevent STIs
Small molecule, antibiotic, sexually transmitted infection - Read more

THE GOOD
Regulatory

Moderna joins FDA rare disease accelerator
mRNA, methylmalonic acidemia, rare disease - Read more

FDA advisory committee recommends updating Covid-19 shots, endorses specific viral lineage as target
Vaccine, Covid-19 - Read more

THE BAD
Approvals & Labels

FDA has a few concerns with Eli Lilly’s Alzheimer’s therapy
Monoclonal antibody, Alzheimer’s - Read more

FDA provides additional data on Vanda Pharmaceuticals insomnia rejection
Small molecule, insomnia - Read more*

*scroll to Page 4 (under “SUPPLEMENTARY INFORMATION”) for the details

THE BAD
Fundraises

Until interest rates drop, Biopharma funding will likely stay as it is, “new normal” - Read more

THE BAD
Strategic Plans

Generics competition doesn’t bode well for Novo Nordisk’s GLP-1 sales in China
GLP-1, weight loss, obesity - Read more

THE UGLY
Marketing

Otsuka makes big transparency mistake, gets scolded by UK’s Prescription Medicines Code Of Practice Authority (PMCPA) - Read more

THE UGLY
Patient Access

9-years later, “Pharma bro” drug Daraprim (Vyera Pharmaceuticals, formerly Turing Pharmaceuticals) is still really expensive
Small molecule, HIV/AIDS - Read more [Paywall]

THE UGLY
Politics & Policy

Italy launches anti-trust probe against Samsung Bioepis, Biogen, Genentech, and Novartis; eye drugs
Biosimilar, antibody, macular degeneration, edema - Read more

Bill to codify right to obtain and use contraceptives doesn’t make it through US Senate - Read more 

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 250+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.